Related Experiment Video

Updated: Apr 13, 2026

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
08:46

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

7.1K

Neonatal sepsis: an old issue needing new answers

Elizabeth Molyneux1, Al Gest2

  • 1Paediatric Department, College of Medicine, Queen Elizabeth Central Hospital, Box 360, Blantyre, Malawi.

The Lancet. Infectious Diseases
|May 2, 2015
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

A Controlled Mouse Model for Neonatal Polymicrobial Sepsis
14:54

A Controlled Mouse Model for Neonatal Polymicrobial Sepsis

Published on: January 27, 2019

12.0K
Non-Invasive Model of Neuropathogenic Escherichia coli Infection in the Neonatal Rat
08:27

Non-Invasive Model of Neuropathogenic Escherichia coli Infection in the Neonatal Rat

Published on: October 29, 2014

11.7K

Related Experiment Videos

Last Updated: Apr 13, 2026

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
08:46

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis

Published on: August 12, 2020

7.1K
A Controlled Mouse Model for Neonatal Polymicrobial Sepsis
14:54

A Controlled Mouse Model for Neonatal Polymicrobial Sepsis

Published on: January 27, 2019

12.0K
Non-Invasive Model of Neuropathogenic Escherichia coli Infection in the Neonatal Rat
08:27

Non-Invasive Model of Neuropathogenic Escherichia coli Infection in the Neonatal Rat

Published on: October 29, 2014

11.7K

Related Concept Videos

Development of the Oral Microbiota01:28

Development of the Oral Microbiota

41
The establishment of the oral microbiome begins before birth, challenging the long-held belief that the fetal oral cavity is sterile. The presence of oral microbes such as Streptococcus and Fusobacterium in amniotic fluid suggests that microbial exposure may occur in utero, potentially through translocation from the maternal oral or gastrointestinal tract. This early colonization primes the neonatal immune system and sets the stage for subsequent microbial succession. Maternal health,...
41

Articles linked to this work by shared authors, journal, and citation graph.

The Frame of Survival for Sepsis: A Practical Systems Framework for Time-Sensitive Critical Illness in Low-Resource Settings.

Critical care medicine·2026

10 Steps to Improve Sepsis Care in Low-Resource Settings.

Critical care medicine·2026

Gaps and Strategies for Management of Sepsis in Low-Resource Settings: Expert Consensus Statements Using a Delphi Method.

Critical care medicine·2026

Developing context-sensitive, comprehensive newborn care protocols: integrating technologies with clinical care pathways for level 2 newborn units in Kenya.

Journal of global health·2025

Significant Impact of Treatment Abandonment on Survival of Children With "Common and Curable" GICC Index Cancers in Sub-Saharan Africa-A Multicenter Prospective CANCaRe Africa Study.

Pediatric blood & cancer·2025

Sustainability of a Cash Transfer Program in Malawi: A CANCaRe Africa "Zero Abandonment" Pilot.

Pediatric blood & cancer·2025

Guiding principles for pragmatic randomised trials of tuberculosis treatments.

The Lancet. Infectious diseases·2026

Clinical, molecular, and in vitro evidence of artemisinin partial resistance in Ethiopian Plasmodium falciparum: a prospective, multisite, surveillance study.

The Lancet. Infectious diseases·2026

Efficacy, immunogenicity, and safety of the 9-valent human papillomavirus vaccine in males aged 16-26 years in Japan: a randomised, double-blind, placebo-controlled trial.

The Lancet. Infectious diseases·2026

A review of Bundibugyo virus and the 2026 outbreak: lessons for epidemic preparedness.

The Lancet. Infectious diseases·2026

Impact of directly observed treatment and extended age range of seasonal malaria chemoprevention with sulfadoxine-pyrimethamine plus amodiaquine in Burkina Faso: a three-group, open-label, cluster-randomised, controlled trial.

The Lancet. Infectious diseases·2026

Baloxavir marboxil, favipiravir, or oseltamivir in patients with non-severe symptomatic seasonal influenza (AD ASTRA): a phase 2, open-label, adaptive, randomised controlled trial.

The Lancet. Infectious diseases·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us